About: Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies
Creator	Anderlini, P Champlin, R Couriel, D De Lima, M Giralt, S Hosing, C Khouri, I Korbling, M Lekakis, L Martin, T Shpall, E
source	PMC
abstract	Cell dose is a critical determinant of outcomes in unrelated cord blood (CB) transplantation. We investigated a strategy in which CB units should contain at least 2 × 10(7) total nucleated cells/kg of recipient weight, otherwise a second unit had to be added. We report the results of a study that was prematurely closed owing to toxicity. Patients with advanced hematologic malignancies without a human leukocyte antigen-matched sibling or unrelated donor were eligible. Conditioning regimen consisted of fludarabine and 12 Gy of total body irradiation (n=11), or melphalan (n=4), with antithymocyte globulin. Graft-versus-host disease prophylaxis was tacrolimus and methotrexate. Fifteen patients with acute leukemia (n=9), chronic myelogenous leukemia (n=2), multiple myeloma (n=2) and lymphoma (n=2) were treated; 60% had relapsed disease at transplantation. Three patients received double CB transplants. The 100-day and 1-year treatment-related mortality rates were 40 and 53%, respectively. Median time to neutrophil and platelet engraftment was 22 days (n=10) and 37 days (n=10), respectively. One patient had secondary graft failure and five patients failed to engraft. Two patients are alive and disease free; 4-year actuarial survival is 33 versus 0% for patients transplanted in remission versus in relapse. We concluded that disease status was the main determinant of treatment failure in this study.
has issue date	2006-08-07(xsd:dateTime)
bibo:doi	10.1038/sj.bmt.1705467
bibo:pmid	16892072
has license	no-cc
sha1sum (hex)	8b82c5610cc923d6b3dc8cad074cc5b304c11349
schema:url	https://doi.org/10.1038/sj.bmt.1705467
resource representing a document's title	Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies
has PubMed Central identifier	PMC7091659
has PubMed identifier	16892072
schema:publication	Bone Marrow Transplant
resource representing a document's body	covid:8b82c5610cc923d6b3dc8cad074cc5b304c11349#body_text
is schema:about of	named entity 'myeloma' named entity 'donor' named entity 'determinant' named entity 'Three' named entity 'transplants' named entity 'cord blood' named entity 'SECONDARY GRAFT FAILURE' named entity 'UNRELATED' named entity 'DETERMINANT' named entity 'ELIGIBLE' named entity 'HUMAN LEUKOCYTE ANTIGEN' named entity 'CLOSED' named entity 'DISEASE PROPHYLAXIS' named entity 'RESULTS' named entity 'DISEASE FREE' named entity 'YEAR' named entity 'DISEASE' named entity 'WEIGHT' named entity 'ADDED' named entity 'TRANSPLANTATION' named entity 'SIBLING' named entity 'DOUBLE' named entity 'patients' named entity 'chronic myelogenous leukemia' named entity 'Graft-versus-host disease' named entity 'Two' named entity 'sibling' named entity 'transplantation' named entity 'study' named entity 'unit' named entity 'advanced' named entity 'patients' named entity 'acute leukemia' named entity 'transplanted' named entity 'human leukocyte antigen' named entity '37 days' named entity 'fludarabine' named entity 'Conditioning regimen' named entity 'tacrolimus' named entity 'methotrexate' named entity 'mortality rates' named entity 'hematologic malignancies' named entity 'toxicity' named entity 'Graft-versus-host disease' named entity 'graft-versus-leukemia effect' named entity 'daclizumab' named entity 'HLA' named entity 'phase II trial' named entity 'melphalan' named entity 'LAK' named entity 'prophylaxis' named entity 'hemopoiesis' named entity 'peripheral blood stem cells' named entity 'transfusion' named entity 'hematopoietic' named entity 'bone marrow' named entity 'steroids' named entity 'relapse' named entity 'DRB1' named entity 'loci' named entity 'Thall' named entity 'TBI' named entity 'HLA-A' named entity 'risk factor' named entity 'mortality rate' named entity 'Cytomegalovirus' named entity 'antithymocyte globulin' named entity 'hematopoietic stem cells' named entity 'human leukocyte antigen' named entity 'risk factor' named entity 'Chimerism'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software